Importantly, anti-NG2 MoAb does not activate either ADCC or CDC cytotoxicity pathways, thus resulting in a lack of cytotoxicity in vitro and in vivo, which further supports the role of NG2 in regulating MLLr-B-ALL blast mobilization to and engraftment in the BM. This evidence concerns the gene CSPG4 and acute lymphoblastic leukemia.